UK stem cell specialist ReNeuron says its loss for the six months ended September 30, 2008, was L3.1 million ($4.6 million), flat with the comparable period the year before.
During this time, the Guildford-based company saw net cash outflow from operating activities of L3.0 million versus L3.1 million, while cash and cash equivalents fell massively to L800,000 from L5.7 million. The firm noted that it had undrawn convertible loan finance of L1.5 million at September 30.
Commenting on the results, company chairman Trevor Jones said: "during the period under review, and subsequently, we have achieved a number of notable goals across the business whilst also completing a significant restructuring and cost-reduction initiative. In order to best position the business for further financing and the future, we have re-focused our efforts on pursuing those programs which make best use of the resources we have available to us and which offer the fastest route to the clinic."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze